МЕДИКАМЕНТОЗНОЕ СОПРОВОЖДЕНИЕ ЧРЕСКОЖНЫХ КОРОНАРНЫХ ВМЕШАТЕЛЬСТВ С ИСПОЛЬЗОВАНИЕМ БИВАЛИРУДИНА: ОБЗОР СОВРЕМЕННЫХ РЕКОМЕНДАЦИЙ
Аннотация
Об авторах
Р. С. ТАРАСОВ
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово, Россия
Россия
Россия
650002, г. Кемерово, Сосновый бульвар, д. 6 Тел. 8 (3842) 64-18-06
В. И. ГАНЮКОВ
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово, Россия
Россия
Россия
Список литературы
1. Ганюков В. И ., Протопопов А. В. Медикаментозное сопровождение чрескожного коронарного вмешательства. Новосибирск; 2014. Ganyukov V. I., Protopopov A. V. Medikamentoznoe soprovozhdenie chreskozhnogo koronarnogo vmeshatel’stva. Novosibirsk; 2014. [In Russ].
2. Синьков М. А., Шилов А. А., Тарасов Р . С., Ганюков В. И . Антикоагулянтное сопровождение чрескожных коронарных вмешательств с использованием бивалирудина или нефракционированного гепарина при различных сосудистых доступах. Комплексные проблемы сердечно-сосудистых заболеваний. 2015; (1): 25–31. DOI: 10.17802/2306-1278-2015-1-25-31. Sinkov M. A., Shilov A. A., Tarasov R. S., Ganyukov V. I. Anticoagulant support of percutaneous coronary interventions with bivalirudin or unfractionated heparin at various vascular accesses. Complex Issues of Cardiovascular Diseases. 2015; (1): 25–31. DOI: 10.17802/2306-1278-2015-1-25-31. [In Russ].
3. Совет экспертов. Текущая позиция по бивалирудну. Российский кардиологический журнал. 2015; 2 (118): 100–102. DOI: 10.15829/1560-4071-2015-02-100-102. Expert consensus. The current position on bivalirudin. Russ. J. Cardiol. 2015; 2 (118): 100–102. DOI: 10.15829/1560-4071-2015-02-100-102. [In Russ].
4. Mehran R., Pocock S., Nikolsky E., Clayton T., Dangas G. D., Kirtane A. J. et al. A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. J. Am. Coll. Cardiol. 2010; 55: 2556–2566.
5. Shahzad A., Kemp I., Mars C., Wilson K., Roome C., Cooper R. et al. Оn behalf of the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014; 7: 2541–2619.
6. Windecker S., Kolh P., Alfonso F. et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart. J. 2014; 35: 2541–2619. DOI: 10.1093/eurheartj/ehu.
7. Lincoff A. M., Kleiman N. S., Kereiakes D. J. et al. Longterm efficacy of bivalirudin and provisional glycoprotein IIb/ IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE- 2 randomized trial. JAMA. 2004; 292 (6): 696–703.
8. Kastrati A., Neumann F. J., Mehilli J. et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary intervention. N. Engl. J. Med. 2008; 359 (7): 688–696.
9. Ndrepepa G., Schulz S., Keta D. et al. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. Am. J. Cardiol. 2010; 105 (2): 163–167.
10. Mahaffey K. W., Lewis B. E., Wildermann N. M. et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main result. J. Invasive Cardiol. 2003; 15 (11): 611–616.
11. Schulz S., Mehilli J., Neumann F. J. et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur. Heart J. 2010; 31 (20): 2482–2491.
12. Montalescot G., White H. D., Gallo R. et al. Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention. N. Engl. J. Med. 2006; 355 (10): 1006–1017.
13. Silvain J., Beygui F., Barthe ´le ´my O., Pollack C. Jr. et al. Efficacy and safety of enoxaparin vs. unfractionated heparin during percutaneous coronary intervention: systematic reviewand meta-analysis. BMJ. 2012; 344.
14. Dumaine R., Borentain M., Bertel O. et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. ArchIntern Med. 2007; 167 (22): 2423–2430.
15. Patrono C., Collet J.-Ph., Mueller Ch. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2015. DOI: 10.1093/eurheartj/ehv320.
16. Petersen J. L., Mahaffey K. W., Hasselblad V. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004; 292: 89–96.
17. Ferguson J. J., Califf R. M., Antman E. M. et al. Enoxaparin vs UFH in high risk patients with NSTEMI with intended early invasive strategy: primary results of SYNERGY randomized trial. JAMA. 2004; 292 (1): 45–54.
18. Cohen M., Levine G. N., Pieper K. S. et al. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc. Interv. 2010; 75: 928–935.
19. Collet J. P., Montalescot G., Golmard J. L. et al. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Am. Heart J. 2004; 147: 655–661.
20. Levine G. N., Ferrando T. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J. Thromb. Thrombolysis. 2004; 17: 167–171.
21. Stone G. W., McLaurin B. T., Cox D. A. et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 2006; 355: 2203–2216.
22. Kastrati A., Neumann F., Schulz S. et al. Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. N. Engl. J. Med. 2011; 365: 1980–1989.
23. Pizzuli L., Zirbes M., Fehske W. et al. Omission of intraveneous heparin and nitroglycerin following uncomplicated coronary angioplasty. Circulation. 1995; 92: 174.
24. Rabah M., Mason D., Muller D. W. et al. Heparin after percutaneous intervention (HAPI): A prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. J. Am. Coll. Cardiol. 1999; 34: 461–467.
25. Batchelor W. B., Mahaffey K. W., Berger P. B. et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J. Am. Coll. Cardiol. 2001; 38: 1608–1613.
26. Yusuf S., Mehta S. R., Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 2006; 354: 1464–1476.
27. Steg P. G., Jolly S. S., Mehta S. R. et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010; 304: 1339–1349.
28. Stone G. W., Witzenbichler B., Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 2008; 358 (21): 2218–2230.
29. Steg P. G., van’t Hof A. W., Hamm C. W. et al. Bivalirudin Started during Emergency Transport for Primary PCI. N. Engl. J. Med. 2013; 369 (23): 2207–2217.
30. Shahzad A., Kemp I., Mars C. et al; for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014. DOI: 10.1016/S0140-6736(14)60924-7.
31. Yusuf S., Mehta S. R., Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295 (13): 1519–1530.
32. O’Gara P. T., Kushner F. G., Ascheim D. D. et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013; 61 (4): 78–140. DOI:10.1016/j.jacc.2012.11.019.
Рецензия
Для цитирования:
ТАРАСОВ Р.С., ГАНЮКОВ В.И. МЕДИКАМЕНТОЗНОЕ СОПРОВОЖДЕНИЕ ЧРЕСКОЖНЫХ КОРОНАРНЫХ ВМЕШАТЕЛЬСТВ С ИСПОЛЬЗОВАНИЕМ БИВАЛИРУДИНА: ОБЗОР СОВРЕМЕННЫХ РЕКОМЕНДАЦИЙ. Комплексные проблемы сердечно-сосудистых заболеваний. 2016;(1):86-94. https://doi.org/10.17802/2306-1278-2016-1-86-94
For citation:
TARASOV R.S., GANYUKOV V.I. BIVALIRUDIN FOR PERCUTANEOUS CORONARY INTERVENTIONS: REVIEW OF CURRENT GUIDELINES. Complex Issues of Cardiovascular Diseases. 2016;(1):86-94. (In Russ.) https://doi.org/10.17802/2306-1278-2016-1-86-94
Просмотров: 787
